Related by context. All words. (Click for frequent words.) 81 confidence interval #.#-#.# 78 % CI #.#-#.# [008] 77 % CI #.#-#.# [007] 76 confidence interval CI 76 % CI #.#-#.# [002] 75 % CI #.#-#.# [006] 75 CI #.#-#.# [001] 74 % CI #.#-#.# [003] 73 CI -#.# 73 % Confidence Interval 73 CI #.#-#.# p = 72 p = .# [002] 72 P = .# 72 CI = 72 aOR 71 % CI #.#-#.# [001] 70 AOR = 70 multivariable adjusted 69 P ≤ 69 % CI #.#-#.# [004] 69 hip BMD 68 lowest tertile 68 TAXUS p value 68 FOLFIRI alone 68 p = NS 67 nonsignificant difference 67 advanced adenoma 67 Hazard Ratio HR 67 p = #.# [003] 67 HbA1C levels 67 -#.# ± [002] 66 NNT = 66 #.#/#.# mmHg [001] 66 TT genotype 66 HbA 1c levels 66 nonfatal MI 66 oxycodone CR 66 achieved ACR# 66 p ≤ 65 p = #.# [004] 65 ALT elevation 65 p = .# [001] 65 -#.# mg dL [001] 65 % CI #.#-#.# [005] 65 placebo p = 65 5-FU/LV 65 HBeAg negative patients 65 nondiabetic patients 65 arterial thromboembolic events 64 p = #.# [002] 64 mIU ml 64 lopinavir r arm 64 adjunctive placebo 64 colorectal adenoma 64 p = 64 Hazard Ratio = 64 highest tertile 64 confidence intervals CIs 64 parous women 64 highest quintile 63 interquartile range 63 creatinine ratio 63 CC genotype 63 Hazard Ratio 63 mmHg diastolic 63 hormone receptor negative 63 Ishak fibrosis score 63 = #.#-#.# 63 recurrent venous thromboembolism 63 multivariate adjusted 63 mean baseline A1C 63 pT3 63 invasive carcinomas 63 tirofiban 63 advanced adenomas 63 biochemical relapse 63 polyp recurrence 63 HF hospitalization 62 LV dysfunction 62 FluCAM arm 62 nonfatal stroke 62 univariate analysis 62 generalized edema 62 p = ns 62 XIENCE V vs. 62 CVD mortality 62 tertile 62 NMIBC 62 recurrent VTE 62 mL/min/#.# m 2 62 x ULN 62 amoxicillin clavulanate 62 lumbar spine BMD 62 experienced virologic failure 62 MADRS score 62 preintervention 62 #.#-#.# p = 62 reinfarction 62 deep venous thromboses 62 nonobese 62 β = 62 mmHg p = 62 placebo dexamethasone 62 nonvertebral fractures 62 locoregional recurrence 62 clinically evaluable patients 61 Operative mortality 61 PSA nadir 61 Secondary endpoints included 61 mg p = 61 Flu Cy 61 mcg QD 61 placebo p 61 â ‰ ¥ 61 tolterodine ER 61 femoral neck BMD 61 baseline HbA1c 61 doxazosin 61 nmol liter 61 oxycodone IR 61 receiving ISENTRESS 61 CR nPR 61 infliximab monotherapy 61 multivariate adjustment 61 Zometa hazard 61 adefovir treated 61 adjunctive ABILIFY 61 severe exacerbations 61 neoplasias 61 receiving VICTRELIS 61 Stent thrombosis 61 nonfasting triglyceride levels 61 HBeAg seroconversion 61 BMS p = 61 nonsignificant 61 preoperative PSA 61 SGPT 61 clodronate 61 MACCE 61 lowest quintile 61 nicardipine 60 μg d 60 statistically significant p = 60 lobular cancer 60 FOLFOX4 60 incidence ≥ 60 mmol l 60 ARCOXIA 60 noncardiac 60 -#.# mg dL [002] 60 comparator arm 60 binary restenosis 60 aged ≥ 60 refractory ischemia 60 ug dose 60 SLNB 60 prednisone prednisolone plus 60 postintervention 60 microbiologically evaluable 60 bilateral oophorectomy 60 methotrexate monotherapy 60 MMSE scores 60 albumin excretion rate 60 invasive lobular 60 TEAEs 60 SGRQ 60 TMP SMX 60 mcg linaclotide 60 PREMPRO 60 linaclotide treated 60 alanine aminotransferase 60 revascularizations 60 KRAS mutations occur 60 FOLFOX4 alone 60 hypertension diabetes mellitus 60 ischemia driven 60 postoperative AF 60 PRADAXA #mg 60 titrated glipizide 60 lifetime abstainers 60 Thal Dex 60 biochemical recurrence 60 BRCA1 mutation carriers 60 regression coefficient 60 Acetate Rectal Suppositories 60 tipranavir r 60 REYATAZ r arm 60 annualized relapse 60 mIU L 60 fluticasone salmeterol 60 leukopenia 60 extracapsular extension 60 conjugated equine estrogens 60 PROCTOCORT ® Suppository Hydrocortisone 60 mU liter 60 mmol liter 60 nmol l 60 g dl 60 LS BMD 60 overt nephropathy 60 leucopenia 60 postoperative complication 60 tertiles 59 endometrial thickness 59 Complication rates 59 morphometric vertebral fractures 59 -#.# log# copies mL 59 euthyroid 59 plus aztreonam 59 = .# 59 nadroparin 59 metoprolol tartrate 59 #mg/day [001] 59 CrCl 59 ß blockers 59 alanine aminotransferase ALT 59 imiquimod cream 59 pmol L 59 #mg BID [001] 59 vertebral fracture 59 ATACAND 59 Cypher Stent 59 progesterone receptor negative 59 extensive metabolizers 59 statistical significance p 59 mL/min/#.# m2 59 nonfatal myocardial infarction 59 mcg kg REBETOL 59 odds ratios ORs 59 MetS 59 bronchioloalveolar carcinoma 59 elevated LDH 59 hypophosphatemia 59 #.#/#.# mm Hg [003] 59 #ng/ml 59 pCR 59 β blockers 59 unresectable HCC 59 CYP#D# inhibitor 59 histologic subtype 59 flutamide 59 IOP lowering 59 -#.# log# 59 chlorambucil 59 sd = 59 liver histology 59 inhospital mortality 59 HBeAg 59 elevated IOP 59 tapentadol ER 59 mmHg systolic 59 distal colon cancer 59 completely resected 59 placebo Hazard Ratio 59 Partial Response 59 HOMA IR 59 rho = 59 dalteparin 59 nonfatal myocardial infarction MI 59 CCyR 59 MMSE score 59 #.#mg/dL 59 nonvertebral fracture 59 lispro 59 baseline serum creatinine 59 neuropathy sensory 59 anastomotic leak 59 ECOG PS 59 fatigue asthenia 59 Secondary endpoints include 59 abacavir lamivudine 59 IQR = 59 IM progesterone 59 hepatorenal syndrome 59 #.#ng/ml 59 perioperatively 59 achieved statistical significance 58 cerebrovascular events 58 DAS# remission 58 sirolimus stent 58 cervix uteri 58 perioperative mortality 58 underwent surgical resection 58 undergone radical prostatectomy 58 neutrophil counts 58 advanced neoplasia 58 fasting triglyceride levels 58 collagenous colitis 58 de novo AML 58 PASI scores 58 acute cholecystitis 58 ATV RTV 58 stage IIIb IV 58 μg L 58 DAS# [002] 58 rizatriptan 58 intravesical therapy 58 hemoglobin A1c HbA1c 58 mcg albinterferon alfa 2b 58 non squamous histology 58 adenoma recurrence 58 log# copies mL 58 colon rectal 58 nmol 58 definite stent thrombosis 58 Fasting plasma glucose 58 nonobstructive 58 anemia hemoglobin 58 malignant neoplasm 58 histological subtype 58 pg ml 58 hemoglobin A1c levels 58 nonvertebral 58 thrombocytopenic 58 ASCUS 58 elevated ALT 58 NSTEMI 58 progression TTP 58 Xalatan R 58 adenomatous polyps 58 mild renal insufficiency 58 ‰ ¥ 58 colorectal adenomas 58 oral allopurinol 58 Adjuvant chemotherapy 58 ≥ 58 certolizumab 58 Pred Forte 58 intima media thickness 58 Cream USP 1 58 eplerenone 58 postop 58 endometrial hyperplasia 58 noncardiovascular mortality 58 vaginal hysterectomy 58 severe neutropenia 58 #Gy 58 histologically confirmed 58 Median PFS 58 mU L 58 HbA1C 58 diastolic BP 58 recurrent UTI 58 receiving XGEVA 58 spontaneous bacterial peritonitis 58 nmol L. 58 venous blood clots 58 ß = 58 SUVmax 58 #.#mmol L [001] 58 μg kg 58 urine albumin 58 abdominal pain abdominal discomfort 58 gestational hypertension 58 leukocyte count 58 overt hepatic encephalopathy HE 58 QTcF 58 4mg/kg 58 glipizide plus 58 TURBT 58 mg + GLY 58 severe periodontitis 58 pg mL 58 moderate renal impairment 58 pmol liter 58 URTI 58 mg d 58 HBeAg negative 58 headache nasopharyngitis 58 graft occlusion 58 achieved CCyR 58 obstructive coronary artery 58 β blocker 58 thromboembolism 58 arterial oxygen saturation 58 systolic blood pressures 58 Lumbar spine 58 posttransplant 58 salmeterol fluticasone propionate 58 biopsy Gleason 58 #.#mmHg 58 squamous histology 58 hypertensives 58 budesonide pMDI 58 -#.# p = 58 systemic corticosteroid 58 nonpregnant women 58 mg kg Hematide 58 symptomatic intracranial hemorrhage 58 hyperlipemia 58 μmol L 58 undetectable HBV DNA 58 underwent resection 58 oral antidiabetic medication 58 micafungin 57 pooled comparator 57 BUPHENYL R sodium phenylbutyrate 57 Taxus Stent 57 PREZISTA r arm 57 WOMAC pain 57 poor metabolizers 57 EBRT 57 symptomatic intracerebral hemorrhage 57 carotid stenosis 57 acarbose 57 recurrent DVT 57 stent binary restenosis 57 attain statistical significance 57 lipid lowering medications 57 enamel defects 57 HbA 1c 57 microbiological eradication 57 latent celiac disease 57 titrated glipizide plus 57 dyspareunia 57 Breslow thickness 57 tumor histology 57 recurrent genital herpes 57 atazanavir ritonavir 57 CIN3 57 radiotherapy RT 57 pamidronate 57 relapsed MM 57 Hb A1C 57 nonmetastatic 57 PLX STROKE targeting 57 urinary bladder cancer 57 mg Androxal 57 nmol L 57 LVSD 57 elevated hsCRP 57 hours postdose 57 neurodevelopmental impairment 57 median PFS 57 insomnia somnolence 57 CR CRu 57 Febrile neutropenia 57 antiretroviral naïve 57 abdominal irradiation 57 bronchoalveolar lavage 57 del 5q MDS 57 rheumatoid factor 57 distant metastasis 57 placebo PBO 57 tamoxifen Nolvadex ® 57 thiazide diuretics 57 proximal DVT 57 advanced hepatocellular carcinoma 57 mitoxantrone plus 57 imipenem 57 EGFR mutation positive 57 GP IIb IIIa inhibitors 57 PaO 2 57 pT2 57 Folfox 57 mcg BID 57 μg liter 57 -#.# ± [001] 57 BARACLUDE ® 57 androgen suppression 57 HbA1c levels 57 nondiabetic 57 hyperlipidaemia 57 radical nephrectomy 57 statistically significant p 57 Infusion Reactions Severe 57 #-#,# mg 57 #OHD 57 ipsilateral stroke 57 nonalcoholic steatohepatitis NASH 57 seroconverted 57 LPV r 57 BMI z 57 XIENCE V demonstrated 57 NIH CPSI 57 -#.# mmol L 57 rebleeding 57 atheroma volume 57 statistically significant predictor 57 cranial irradiation 57 intact parathyroid hormone 57 GERD symptom 57 glycated hemoglobin levels 57 perimenopausal women 57 benign noncancerous 57 virologic failure 57 obstructive CAD 57 pyrexia mucositis sepsis febrile 57 CDAI score 57 -#.# mm Hg 57 XIENCE V PROMUS Stent 57 invasive ductal 57 cilostazol 57 nonfasting 57 reintubation 57 achieved mucosal healing 57 rimonabant #mg 57 BENICAR HCT 57 AUC0 57 patients undergoing CABG 57 mg ustekinumab 57 venous thromboembolic disease 57 diastolic blood pressures 57 min -1 57 troponin T 57 achieved PASI 57 using lactulose concomitantly 57 ezetimibe simvastatin 57 HBeAg positive patients 57 OS = ISD/#/#/# 57 ErbB2 positive 57 transferrin saturation 57 spine BMD 57 posttreatment 57 VcMP 57 thromboembolic events 57 #mg BID [003] 57 bivalirudin monotherapy 57 nonischemic 57 NPH insulin 57 anaplastic astrocytomas 57 umol L 57 piperacillin tazobactam 57 placebo fluoxetine 57 DAS# CRP 57 perioperative complications 57 nondiabetics 57 colorectal neoplasia 57 benazepril 57 vs.# 57 oral hypoglycemic agent 57 colorectal carcinoma 57 biphasic insulin aspart 57 DJI #.# 57 mL sec 57 #.#g/day 57 clinically evaluable 57 serum creatinine levels 57 pancreatic resection 57 rectal tenesmus 57 sUA 57 Vancocin p = 57 ALT normalization 57 lymphadenectomy 57 Papillary 57 PSADT 57 ejection fractions 57 prevalences 57 Univariate analysis 57 salmeterol fluticasone 57 seropositivity 57 #.#/# [005] 57 Charlson comorbidity index 57 nonmelanoma skin cancers 57 cough dyspnea 57 plus dexamethasone 56 low dose Iluvien 56 #.#mmol L [002] 56 plus medroxyprogesterone acetate 56 hyperhomocysteinemia 56 periprocedural 56 COPD exacerbation 56 baseline A1C 56 Triamcinolone 56 mg hydrochlorothiazide 56 mg BID dose 56 Viread Emtriva Sustiva 56 noninferior 56 dizziness nausea diarrhea 56 μg mL 56 elevated transaminases 56 preoperative chemotherapy 56 mild renal impairment 56 revascularization procedures 56 complete cytogenetic response 56 IIIa inhibitors 56 GG genotype 56 metastatic GIST 56 mg QD 56 underwent percutaneous coronary 56 #.#,#.# [002] 56 TPV r 56 #mg/day [002] 56 ACTEMRA TM 56 achieved sustained virological 56 lopinavir r 56 lymphocytosis 56 tHcy 56 TAXUS Express Stent 56 carotid artery blockage 56 non menthol smokers 56 luminal diameter 56 lumbar spine bone 56 BENICAR 56 ertapenem 56 CIN3 + 56 carotid intima media 56 adverse reactions occurring 56 rectal tenesmus #.# 56 events MACE 56 dysplastic nevi 56 T2 lesion volume 56 folic acid takers 56 milliliters mL 56 Mg Uk 56 EDSS score 56 glulisine 56 baseline FEV 56 inversely associated 56 n = 56 CHD mortality 56 trimethoprim sulfamethoxazole 56 HIV coinfected 56 LOVENOX 56 univariate analyzes 56 asthenia fatigue 56 log# IU mL 56 contrast induced nephropathy 56 beta carotene supplementation 56 HIV uninfected 56 cardiovascular mortality 56 DES implantation 56 lobular carcinoma 56 microg 56 adriamycin 56 receiving PEGINTRON 56 #mmHg [001] 56 severe hypoglycemic 56 mucosal inflammation 56 hydroxyvitamin D levels 56 octreotide LAR 56 adverse reactions incidence 56 anthracycline taxane 56 highly emetogenic 56 Kaplan Meier analysis 56 lipid lowering agents 56 segment binary restenosis 56 estrogen receptor negative 56 REMICADE monotherapy 56 TDF FTC 56 cisplatin vinorelbine 56 ACR# ACR# 56 diabetes mellitus DM 56 #.#-#.# [011] 56 NSTE ACS 56 treat NNT 56 postmenopausal osteoporotic women 56 Crohn Disease Activity 56 multivariate Cox 56 breastfed exclusively 56 nonobese patients 56 laboratory abnormalities 56 sternal wound infections 56 events TEAEs 56 caspofungin 56 cGy 56 EDSS scores 56 stent thromboses 56 CRu 56 conjugated equine estrogen 56 recurrent acute pancreatitis 56 Visual Analogue Scale VAS 56 diastolic hypertension 56 BMI ≥ 56 pretest probability 56 systolic dysfunction 56 inhospital 56 glimepiride 56 mm Hg diastolic 56 CIN2 + 56 postoperative morbidity 56 bypass graft CABG surgery 56 recurrent myocardial infarction 56 8mg/kg 56 systemic embolism 56 transaminase elevations 56 LV ejection fraction 56 moderately emetogenic 56 IQR 56 polytherapy 56 mEq L 56 uM 56 triglyceride concentrations 56 R entecavir 56 logMAR 56 diameter stenosis 56 Partial Responses 56 nasopharyngitis headache 56 undergoing coronary artery 56 Basal Cell 56 racemic albuterol 56 CRp 56 febrile neutropenia 56 headache abdominal pain 56 symptomatic carotid stenosis 56 conjunctival hyperemia 56 chemoradiation therapy 56 receiving Vectibix monotherapy 56 tobramycin inhalation solution 56 Radical prostatectomy 56 FluCAM 56 PANSS scores 56 BPH Symptom Score 56 kappa = 56 bivalirudin alone 56 adiponectin concentrations 56 VaD 56 idiopathic PAH 56 prior relapsers 56 NYHA functional class 56 hypokalemia 56 mL kg 56 nadolol 56 tipranavir ritonavir 56 dysuria 56 interval #.#-#.# 56 bioavailable testosterone 56 neutropenia dehydration dyspnea 56 mg simvastatin 56 echocardiographic parameters 56 FDA defined valvulopathy 56 rFSH 56 baseline LDH 56 atorvastatin #mg 56 HDL LDL ratio 56 symptomatic VTE 56 postoperative chemotherapy 56 tibiofemoral 56 systolic BP 56 PANSS total 56 serum concentrations 56 peripheral sensory neuropathy 56 triglyceride concentration 55 thromboembolic disease 55 plus MTX 55 lamivudine monotherapy 55 stomatitis pharyngitis 55 fatal pulmonary embolism 55 ug ml 55 See WARNINGS 55 ARB telmisartan 55 acneform rash 55 QIDS SR 55 BRCA2 carriers 55 KRAS mutant tumors 55 thyrotropin levels 55 nonischemic cardiomyopathy 55 elevated triglyceride levels 55 BCG vaccinated 55 IPAH 55 mso footer margin 55 atrophic gastritis 55 PCa 55 HIV HCV coinfected 55 non splenectomized 55 kg m² 55 ductal cancer 55 PSQI 55 binary restenosis rate 55 serum aminotransferase levels 55 hMG 55 glycated hemoglobin HbA1c 55 receiving prophylactic anticoagulation 55 anthracycline containing 55 Hb A1c 55 shorter telomere length 55 CK # plasma concentrations 55 cases/# 55 hypoglycemic events 55 ENDOMETRIN 55 aldosterone antagonist 55 aspartate aminotransferase 55 indinavir 55 BRCA mutation carriers 55 & s2 = 55 serum triglycerides 55 mycophenolate 55 hematological parameters 55 neutropaenia 55 kcal d 55 esophagogastroduodenoscopy 55 serum lipid levels 55 recurrent coronary 55 radical prostatectomy RP 55 hypogonadal 55 smoldering myeloma 55 PCWP 55 underwent CABG 55 subclinical hyperthyroidism 55 seminal vesicle invasion 55 fructosamine 55 nasopharyngitis 55 mg qd 55 renal insufficiency 55 psychiatric comorbidities 55 ropivacaine 55 plus OBT 55 ALT flares 55 plus GP IIb 55 ratio ICER 55 chlorthalidone 55 serum sodium levels 55 atypical hyperplasia 55 operable breast cancer 55 Score DAS# 55 malignancy HCM 55 NNRTI resistance 55 pulsatility index 55 #.#-#.# [002] 55 liposomal amphotericin B 55 neurologic complications 55 glycoprotein IIb IIIa inhibitors 55 HAM D# scores 55 gallbladder disease 55 non valvular atrial 55 Viread Emtriva 55 adenoma detection 55 Serum creatinine 55 external genital lesions 55 detemir 55 Viread Emtriva SUSTIVA 55 Stomatitis 55 postoperative pulmonary 55 unfractionated heparin 55 recurrent ischemia 55 prospectively stratified 55 serum homocysteine 55 AUCs 55 NATRECOR R 55 cervical intraepithelial neoplasia 55 efavirenz EFV 55 Kaplan Meier estimates 55 intravenous diuretics 55 corticosteroid dose 55 nevirapine Viramune 55 distal colon 55 Engerix B 55 undergoing CABG 55 R adefovir dipivoxil 55 Postoperative complications 55 mitoxantrone 55 endoscopic remission 55 pulmonary dysfunction 55 impaired glucose metabolism 55 receiving golimumab 55 noncardiovascular 55 NOLVADEX 55 serum magnesium 55 oral squamous cell 55 contralateral breast 55 tamsulosin 55 multivessel disease 55 coronary calcification 55 RBC transfusion 55 mEq 55 fluorouracil leucovorin 55 glyburide 55 abnormal cytology 55 apolipoprotein B 55 oral diclofenac 55 VT VF 55 Lucentis monotherapy 55 Free Survival PFS 55 thromboembolic complications 55 solifenacin 55 undergoing liver transplantation 55 recurrent atrial fibrillation 55 albumin excretion 55 aspirin clopidogrel 55 MCyR 55 Postoperatively 55 IBDQ 55 symptomatic GERD 55 ng dL 55 μg dL 55 nondrinkers 55 interquartile range IQR 55 angiotensin II receptor blockers 55 % AST SGOT 55 receiving INTRON 55 response CCyR 55 Key secondary endpoints 55 A1c levels 55 thromboembolic 55 sociodemographic characteristics 55 undergoing radical prostatectomy 55 diabetes mellitus hypertension 55 cells uL 55 paresthesias 55 axillary node dissection 55 DAS# scores 55 hypovitaminosis D 55 lymphocyte count 55 restenosis reblockage 55 interferon ribavirin 55 candesartan cilexetil 55 hematologic abnormalities 55 median survivals 55 chlamydial infection 55 beta blocker therapy 55 thrombosis embolism 55 Doxil ® 55 e antigen HBeAg 55 ipsilateral breast 55 #mg doses [002] 55 LVEF 55 mm Hg systolic 55 QVAR R 55 fatal IHD 55 voriconazole 55 Erythropoietic therapies may 55 log# reduction 55 macrovascular events 55 3mg/kg 55 comorbidities 55 normotensive 55 labetalol 55 leuprorelin 55 IFN alfa 55 hypercalciuria 55 undergoing radical cystectomy 55 underwent radical prostatectomy 55 Arch Intern Med 55 nonpregnant 55 serum selenium 55 elevated fasting glucose 55 Pneumocystis carinii pneumonia 55 acute myocardial infarctions 55 detrusor overactivity 55 abdominal circumference 55 salpingo oophorectomy 55 symptomatic intracranial 55 venlafaxine XR 55 T1c 55 proctitis 55 Baseline characteristics 55 pretransplant 55 undetectable viral 55 asthma exacerbation 55 intratympanic 55 Posaconazole 55 coronary revascularization procedures 54 acute respiratory tract infections 54 creatine phosphokinase 54 baseline CD4 54 FLOMAX 54 CHD CVD 54 MIC# [001] 54 symptom exacerbation 54 Calcium intake 54 Drug eluting stent 54 metronidazole gel 54 mean baseline HbA1c 54 ± SD 54 APTIVUS r 54 primary aldosteronism 54 RLAI 54 hypercholesterolaemia 54 cerebrovascular accidents 54 basal cell carcinoma BCC 54 kg/m2 54 tibolone 54 HNSCC 54 distant metastases 54 pulmonary capillary wedge 54 visceral metastases 54 CsA 54 erythrocyte sedimentation rate 54 fluticasone propionate FP 54 azathioprine 54 Consensus +#.# 54 cirrhotic 54 mediastinitis 54 surgically resectable 54 comorbid illnesses 54 CYPHER ® 54 dehydroepiandrosterone sulfate 54 nulliparous women 54 clinically meaningful reductions 54 MBq 54 antibody titer 54 intracerebral haemorrhage 54 prespecified secondary 54 ALND 54 osteopenic 54 IPSS 54 haematologic 54 nonaspirin 54 timepoints 54 hemorrhagic complications 54 mutated K ras 54 attending antenatal clinics 54 paclitaxel eluting stents 54 postdischarge 54 ximelagatran 54 repeat revascularization 54 haemorrhagic stroke 54 atherosclerotic CVD 54 eptifibatide